Stage III Colon Cancer AJCC v8

17 clinical trials · Condition

Record	Firm	Date
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCT05308446)	National Cancer Institute (NCI)	2022-07-19
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)	National Cancer Institute (NCI)	2021-08-09
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183)	M.D. Anderson Cancer Center	2020-12-02
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140)	M.D. Anderson Cancer Center	2020-10-14
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839)	City of Hope Medical Center	2020-05-27
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456)	Academic and Community Cancer Research United	2020-04-24
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial (NCT03765736)	Academic and Community Cancer Research United	2020-04-20
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (NCT04109924)	Roswell Park Cancer Institute	2019-12-27
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer (NCT03592641)	National Cancer Institute (NCI)	2019-07-25
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment (NCT03516942)	ECOG-ACRIN Cancer Research Group	2018-06-11
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)	National Cancer Institute (NCI)	2017-10-16

Track Stage III Colon Cancer AJCC v8 automatically

Every clearance here is in the API, with alerts when new ones post.